• Discounts and special offers
  • Subscriber-only articles and interviews
  • Breaking news and trending topics

Already a subscriber?

By signing up, you accept Moneywise's Terms of Use, Subscription Agreement, and Privacy Policy.

Not interested ?

Nuveen Real Estate Income Fund (JRS)

There is a reason why many investors tend to gravitate towards real estate: it has created more wealth than all other asset classes combined.

It also acts as a hedge against inflation: as the price of raw materials and labor goes up, new properties are more expensive to build. And that drives up the price of existing real estate.

As rental prices go up across the country in this inflationary environment, real estate investors have an opportunity to earn increased income.

Nuveen Real Estate Income Fund is a closed-end fund focusing on this particular sector. Its objective is “high current income and capital appreciation.”

The fund invests in income-producing common stocks, preferred stocks, convertible preferred stocks, and debt securities issued by companies in the real estate sector.

Notably, at least 75% of assets managed by JRS will be invested in investment-grade rated securities.

As of June 30, the fund’s top five industries were specialized REITs (21.3%), residential REITs (21.1%), office REITs (14.9%), retail REITs (14.5%), and industrial REITs (12.3%).

JRS pays quarterly distributions of 20.90 cents per share, which translates to an annual yield of 8.6%.

The fund has a net asset value of $10.12 per share and a share price of $9.72 — meaning it’s trading at roughly a 4% discount to its NAV.

Invest in real estate without the headache of being a landlord

Imagine owning a portfolio of thousands of well-managed single family rentals or a collection of cutting-edge industrial warehouses. You can now gain access to a $1B portfolio of income-producing real estate assets designed to deliver long-term growth from the comforts of your couch.

The best part? You don’t have to be a millionaire and can start investing in minutes.

Learn More

Tekla Healthcare Opportunities Fund (THQ)

Healthcare serves as a classic example of a defensive sector thanks to its lack of correlation with the ups and downs of the economy.

Income-seeking investors can use Tekla Healthcare Opportunities Fund to tap into the sector.

This closed-end fund invests across all healthcare sub-sectors and across a company’s capital structure. Its largest sector exposures were pharmaceuticals (29.0%), health care providers & services (24.7%), biotechnology (13.7%), health care equipment & supplies (13.6%), and medical devices and diagnostics (5.6%) at the end of June.

You can find many industry heavyweights in THQ’s portfolio, such as UnitedHealth Group, Johnson & Johnson, AbbVie, Pfizer, and Cigna.

Here’s the neat part: While most dividend-paying companies follow a quarterly distribution schedule, Tekla Healthcare Opportunities Fund pays shareholders on a monthly basis.

Right now, the fund has a monthly distribution rate of 11.25 cents per share, which comes out to an annual yield of 6.7%.

THQ currently trades at $20.09 per share — around a 7.5% discount to its NAV of $21.73 per share.

Sponsored

Follow these steps if you want to retire early

Secure your financial future with a tailored plan to maximize investments, navigate taxes, and retire comfortably.

Advisor is an online platform that can match you with a network of vetted fiduciary advisors who are evaluated based on their credentials, education, experience, and pricing. The best part? - there is no fee to find an advisor.

Jing Pan Investment Reporter

Jing is an investment reporter for MoneyWise. He is an avid advocate of investing for passive income. Despite the ups and downs he’s been through with the markets, Jing believes that you can generate a steadily increasing income stream by investing in high quality companies.

Disclaimer

The content provided on Moneywise is information to help users become financially literate. It is neither tax nor legal advice, is not intended to be relied upon as a forecast, research or investment advice, and is not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. Tax, investment and all other decisions should be made, as appropriate, only with guidance from a qualified professional. We make no representation or warranty of any kind, either express or implied, with respect to the data provided, the timeliness thereof, the results to be obtained by the use thereof or any other matter. Advertisers are not responsible for the content of this site, including any editorials or reviews that may appear on this site. For complete and current information on any advertiser product, please visit their website.